ImmuneOncia Therapeutics, Inc. (KOSDAQ:424870)

ImmuneOncia Therapeutics Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	8,894	8,238	8,226	20,957	26,730	36,320
Short-Term Investments	10,100	15,200	3,100	5,000	-	6,000
Cash & Short-Term Investments	18,994	23,438	11,326	25,957	26,730	42,320
Cash Growth	67.70%	106.93%	-56.36%	-2.89%	-36.84%	104.10%
Accounts Receivable	-	-	421.83	11	633.65	-
Other Receivables	179	128.37	7,709	172.13	202.16	41.53
Receivables	179	128.37	8,131	183.13	835.81	41.53
Prepaid Expenses	1,376	2,475	297.34	376.95	520.18	232.62
Other Current Assets	507.98	465.54	107.93	118.97	884.02	72.89
Total Current Assets	21,057	26,506	19,863	26,636	28,970	42,667
Property, Plant & Equipment	603.87	649	494.54	892.1	547.33	997.96
Other Intangible Assets	4,379	4,503	4,908	5,429	5,987	6,503
Other Long-Term Assets	1,511	1,487	930.02	838.32	188.36	932.89
Total Assets	27,550	33,146	26,195	33,795	35,693	51,101

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accrued Expenses	138.88	138.88	137.63	103.34	154.4	128.24
Current Portion of Leases	43.34	54.98	51.05	50.11	98.69	216.39
Current Unearned Revenue	1,950	1,950	1,950	1,950	1,950	6,902
Other Current Liabilities	1,773	2,115	4,354	1,268	1,646	1,578
Total Current Liabilities	3,906	4,259	6,493	3,372	3,850	8,824
Long-Term Leases	12.35	14.55	44.01	86.83	24.27	98.24
Pension & Post-Retirement Benefits	193.36	139.2	15.06	14.27	-	184.09
Other Long-Term Liabilities	323.21	317.13	219.18	236.63	84,226	101,526
Total Liabilities	4,435	4,730	6,771	3,710	88,100	110,633

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	37,182	37,083	36,365	26,896	26,141	25,503
Additional Paid-In Capital	116,206	115,752	79,021	35,292	28,046	22,148
Retained Earnings	-143,709	-138,091	-110,721	-105,016	-113,921	-110,518
Comprehensive Income & Other	13,437	13,672	14,759	8,637	7,326	3,336
Total Common Equity	23,115	28,415	19,424	-34,192	-52,407	-59,532
Shareholders' Equity	23,115	28,415	19,424	30,086	-52,407	-59,532
Total Liabilities & Equity	27,550	33,146	26,195	33,795	35,693	51,101

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	55.7	69.53	95.06	136.94	122.97	314.63
Net Cash (Debt)	18,938	23,368	11,231	25,820	26,607	42,005
Net Cash Growth	68.62%	108.06%	-56.50%	-2.96%	-36.66%	103.58%
Net Cash Per Share	259.61	332.76	199.46	492.28	510.53	904.13
Filing Date Shares Outstanding	74.36	74.17	56.31	52.45	52.12	46.46
Total Common Shares Outstanding	74.36	74.17	56.31	52.45	52.12	46.46
Working Capital	17,151	22,247	13,370	23,264	25,120	33,842
Book Value Per Share	310.84	383.14	344.97	-651.90	-1005.59	-1281.39
Tangible Book Value	18,737	23,913	14,516	-39,621	-58,394	-66,035
Tangible Book Value Per Share	251.96	322.42	257.81	-755.41	-1120.48	-1421.36
Machinery	1,823	1,797	1,514	1,443	1,173	1,148

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 9, 2026

Data Sources Report a data error